Monte Rosa Therapeutics, Inc. (GLUE): who owns it and who trades it
As of Nov 16, 2026, GLUE insiders reported 35 open-market sales worth $4M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Filip Janku (Chief Medical Officer), with $1.3M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Monte Rosa Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns GLUE
194 funds and institutions reported GLUE shares worth $2.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is T. Rowe Price Associates with 11.1%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| T. Rowe Price Associates | 8.86M | 11.07% | $214M | +32% |
| NEA Management Company, LLC | 7.69M | 9.61% | $186M | No change |
| BlackRock, Inc. | 6.84M | 8.55% | $166M | +21% |
| TCG Crossover Management, LLC | 4.62M | 5.78% | $112M | No change |
| Vestal Point Capital, LP | 4.60M | 5.75% | $111M | +28% |
| Bvf Inc | 4.46M | 5.58% | $108M | No change |
| Baker Bros. Advisors LP | 4.35M | 5.43% | $105M | No change |
| State Street Corp | 3.73M | 4.66% | $90.3M | +11% |
| Montanova Capital, LLC | 3.55M | 4.44% | $85.9M | -16% |
| Vanguard Capital Management LLC | 3.41M | 4.27% | $82.6M | +10% |
| Versant Venture Management, LLC | 3.18M | 3.98% | $77M | No change |
| Braidwell LP | 2.45M | 3.06% | $59.3M | -24% |
| Geode Capital Management, LLC | 1.86M | 2.33% | $45.1M | +21% |
| American Century Companies Inc | 1.62M | 2.03% | $39.3M | -42% |
| Marshall Wace, LLP | 1.59M | 1.99% | $38.6M | +11% |
| Aisling Capital Management LP | 1.56M | 1.94% | $37.6M | No change |
| California State Teachers Retirement System | 1.31M | 1.64% | $54.2M | – |
| Nantahala Capital Management, LLC | 1.30M | 1.63% | $31.6M | +100% |
| Bellevue Group AG | 1.19M | 1.49% | $28.8M | -5% |
| Dimensional Fund Advisors LP | 1.18M | 1.47% | $28.5M | +13% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, GLUE insiders reported $0 of open-market purchases and $4M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Matthew Bowen | Principal Accounting Off | Sale | 13 | $10.56 | $137 | Form 4 |
| Jul 16, 2026 | Markus Warmuth | CEO | Sale | 9,500 | $23.18 | $220K | Form 4 |
| Jul 15, 2026 | Jennifer Champoux | Chief Operating Officer | Sale | 4,351 | $23.38 | $102K | Form 4 |
| Jul 6, 2026 | Sharon Townson | Chief Scientific Officer | Sale | 400 | $24.13 | $9.7K | Form 4 |
| Jul 6, 2026 | Sharon Townson | Chief Scientific Officer | Sale | 5,600 | $23.25 | $130K | Form 4 |
| Jun 30, 2026 | Filip Janku | Chief Medical Officer | Sale | 5,407 | $24.50 | $132K | Form 4 |
| Jun 29, 2026 | Filip Janku | Chief Medical Officer | Sale | 6,000 | $22.95 | $138K | Form 4 |
| Jun 29, 2026 | Anthony M. Manning | Director | Sale | 10,000 | $23.11 | $231K | Form 4 |
| Jun 24, 2026 | Filip Janku | Chief Medical Officer | Sale | 30,000 | $21.42 | $643K | Form 4 |
| Jun 23, 2026 | Filip Janku | Chief Medical Officer | Sale | 11,845 | $20.22 | $240K | Form 4 |
| Jun 23, 2026 | Sharon Townson | Chief Scientific Officer | Sale | 3,000 | $20.00 | $60K | Form 4 |
| Jun 23, 2026 | Jennifer Champoux | Chief Operating Officer | Sale | 2,175 | $20.00 | $43.5K | Form 4 |
| Jun 17, 2026 | Jennifer Champoux | Chief Operating Officer | Sale | 2,176 | $19.00 | $41.3K | Form 4 |
| Jun 17, 2026 | Sharon Townson | Chief Scientific Officer | Sale | 3,000 | $19.00 | $57K | Form 4 |
| Jun 1, 2026 | Markus Warmuth | CEO | Sale | 4,998 | $19.41 | $97K | Form 4 |
| Jun 1, 2026 | Markus Warmuth | CEO | Sale | 468 | $19.73 | $9.2K | Form 4 |
| May 29, 2026 | Sharon Townson | Chief Scientific Officer | Sale | 6,000 | $19.87 | $119K | Form 4 |
| May 27, 2026 | Jennifer Champoux | Chief Operating Officer | Sale | 2,175 | $20.00 | $43.5K | Form 4 |
| May 22, 2026 | Jennifer Champoux | Chief Operating Officer | Sale | 2,176 | $19.00 | $41.3K | Form 4 |
| May 21, 2026 | Anthony M. Manning | Director | Sale | 10,000 | $18.01 | $180K | Form 4 |
| May 1, 2026 | Markus Warmuth | CEO | Sale | 5,467 | $18.92 | $103K | Form 4 |
| Apr 14, 2026 | Markus Warmuth | CEO | Sale | 8,000 | $17.64 | $141K | Form 4 |
| Apr 9, 2026 | Philip Nickson | Chief Business & Legal O | Sale | 5,845 | $17.69 | $103K | Form 4 |
| Mar 4, 2026 | Edmund Dunn | Principal Accounting Off | Sale | 139 | $17.96 | $2.5K | Form 4 |
| Mar 2, 2026 | Markus Warmuth | CEO | Sale | 5,466 | $17.92 | $98K | Form 4 |
| Mar 2, 2026 | Edmund Dunn | Principal Accounting Off | Sale | 536 | $17.50 | $9.4K | Form 4 |
| Feb 27, 2026 | Edmund Dunn | Principal Accounting Off | Sale | 25,164 | $18.10 | $455K | Form 4 |
| Feb 23, 2026 | Filip Janku | Chief Medical Officer | Sale | 9,189 | $19.50 | $179K | Form 4 |
| Jan 7, 2026 | Markus Warmuth | CEO | Sale | 309 | $24.57 | $7.6K | Form 4 |
| Jan 7, 2026 | Markus Warmuth | CEO | Sale | 1,450 | $23.88 | $34.6K | Form 4 |
| Jan 7, 2026 | Markus Warmuth | CEO | Sale | 3,707 | $23.24 | $86.2K | Form 4 |
| Jan 5, 2026 | Philip Nickson | Chief Business & Legal O | Sale | 3,155 | $15.17 | $47.9K | Form 4 |
| Jan 5, 2026 | Jennifer Champoux | Chief Operating Officer | Sale | 2,629 | $15.17 | $39.9K | Form 4 |
| Jan 5, 2026 | Edmund Dunn | Principal Accounting Off | Sale | 1,039 | $15.17 | $15.8K | Form 4 |
| Jan 5, 2026 | Markus Warmuth | CEO | Sale | 10,135 | $15.17 | $154K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Filip Janku | Chief Medical Officer | – | $1.3M | Jun 30, 2026 |
| Markus Warmuth | President & CEO, Director | – | $951K | Jul 16, 2026 |
| Edmund Dunn | Principal Accounting Officer | – | $483K | Mar 4, 2026 |
| Anthony M. Manning | Director | – | $411K | Jun 29, 2026 |
| Sharon Townson | Chief Scientific Officer | – | $376K | Jul 6, 2026 |
| Jennifer Champoux | Chief Operating Officer | – | $311K | Jul 15, 2026 |
| Philip Nickson | Chief Business & Legal Officer | – | $151K | Apr 9, 2026 |
| Matthew Bowen | Principal Accounting Officer | – | $137 | Oct 5, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
GLUE short interest
Very high short interest. 24.4% of GLUE shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 39%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 20.86M GLUE shares were sold short, 24.4% of the shares outstanding, up 0.9% from the report before. At the average daily volume of 1.33M shares, buying them all back would take about 15.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 20.86M | 24.41% | +1% | 1.33M | 15.7 |
| Oct 15, 2026 | 20.66M | 24.22% | +5% | 1.84M | 11.2 |
| Sep 30, 2026 | 19.69M | 23.08% | +2% | 1.09M | 18.0 |
| Sep 15, 2026 | 19.27M | 22.58% | +7% | 1.13M | 17.1 |
| Aug 31, 2026 | 18.08M | 21.19% | +4% | 1.09M | 16.6 |
| Aug 14, 2026 | 17.46M | 20.46% | +6% | 1.25M | 14.0 |
| Jul 31, 2026 | 16.46M | 19.29% | -4% | 1.55M | 10.6 |
| Jul 15, 2026 | 17.20M | 21.49% | -8% | 1.31M | 13.1 |
| Jun 30, 2026 | 18.63M | 23.29% | +9% | 2.20M | 8.5 |
| Jun 15, 2026 | 17.17M | 21.46% | +7% | 1.03M | 16.6 |
| May 29, 2026 | 16.01M | 20.00% | +7% | 832,953 | 19.2 |
| May 15, 2026 | 14.96M | 18.70% | -1% | 725,334 | 20.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Monte Rosa Therapeutics company events
Monte Rosa Therapeutics filed 12 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 1, 2026AnnouncementThe Company announced positive data from GFORCE-1, a Phase 1 study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of NLRP3/IL-1-driven inflammatory diseases. Filing
- Sep 8, 2026AnnouncementAs previously disclosed, the Company is party to a global exclusive development and commercialization license agreement with Novartis pursuant to which Novartis has exclusive worldwide rights to develop, manufacture and commercialize VAV1-directed MGDs, including MRT-6160 (DDY391). Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 11, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 17, 2026ResultsReleased financial results. Filing
- Feb 10, 2026LeadershipEdmund Dunn informed us of his intent to retire from the role of SVP, Corporate Controller and Principal Accounting Officer of Monte Rosa Therapeutics, Inc., effective as of April 3, 2026. Filing
- Jan 9, 2026AgreementMonte Rosa Therapeutics, Inc. entered into an Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters listed on Schedule 1 thereto, related to an underwritten public offering of 11,125,000 shares of the Company’s… Filing
- Jan 7, 2026AnnouncementMonte Rosa Therapeutics, Inc. terminated the sales agreement prospectus filed with the Company’s registration statement on Form S-3 (File No. 333-285942) and related to the shares of the Company’s common stock, par value $0.0001 per share, issuable pursuant to the Open Market Sale Agreement, dated… Filing
- Jan 7, 2026AnnouncementThe Company announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6. Filing
- Dec 16, 2025AnnouncementThe Company announced positive interim data from its ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic CRPC. The Phase 1/2 study evaluated 0.5 mg and 0.75 mg of MRT-2359 administered orally on a 21-days-on… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Monte Rosa Therapeutics financials
Famous investors that hold GLUE
5 of the 50 well-known investors we track reported holding GLUE in their latest 13F filing. The largest position is Ken Griffin's, worth $10.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 857,107 | $10.2M | 0.0% | +424% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 770,673 | $9.2M | 0.0% | New |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 295,844 | $3.5M | 0.0% | -19% |
| Israel Englander · Millennium Management | Q3 2026 | 161,037 | $1.9M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 42,597 | $508K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named GLUE in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 2.6% |
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 8.6% |
| Nov 16, 2026 | Vestal Point Capital, LP | 13G/A | 8.4% |
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 2.6% |
| Nov 16, 2026 | TCG Crossover GP II, LLC | 13G/A | 2.2% |
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 8.6% |
| Nov 16, 2026 | TCG Crossover GP II, LLC | 13G/A | 2.2% |
| Nov 16, 2026 | Vestal Point Capital, LP | 13G/A | 8.4% |
Questions about Monte Rosa Therapeutics, Inc. (GLUE) stock
Who owns the most GLUE stock?
The largest reported owner of Monte Rosa Therapeutics, Inc. (GLUE) is T. Rowe Price Associates, with 11.1% of the company. In total, 194 funds and institutions reported holding GLUE at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are GLUE insiders buying or selling?
In the last 12 months, GLUE insiders reported no open-market purchases and 35 sales worth $4M. The latest trade was on Oct 5, 2026. See every trade.
What is the short interest in GLUE?
As of Oct 30, 2026, 20.86M GLUE shares were sold short, 24.4% of the shares outstanding, up 0.9% from the report before. At the average daily volume of 1.33M shares, buying them all back would take about 15.7 trading days (days to cover). See the history.
Which famous investors hold GLUE?
5 of the 50 well-known investors we track reported GLUE in their latest 13F filing, including Ken Griffin, Steve Cohen, Ken Fisher. The largest position is worth $10.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.